A phase II study of gemcitabine in patients with malignant pleural mesothelioma-Reference-Cited by-同舟云学术

A phase II study of gemcitabine in patients with malignant pleural mesothelioma

Published:1999-06-15 Issue:12 Volume:85 Page:2577-2582
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

van Meerbeeck Jan P.,Baas Paul,Debruyne Channa,Groen Harry J.,Manegold Chris,Ardizzoni Andrea,Gridelli Cesare,van Marck Eric A.,Lentz MarieAnge,Giaccone Giuseppe,

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference25 articles.

1. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.

2. Factors Predictive of Survival Among 337 Patients With Mesothelioma Treated Between 1984 and 1994 by the Cancer and Leukemia Group B

3. Chemotherapy in malignant pleural mesothelioma. A review.

4. Malignant pleural mesothelioma

5. Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group

Cited by 119 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New Treatment for Pleural Mesothelioma;Haigan;2024-08-20

2. Epidemiologie, Diagnostik und Therapie des Pleuramesothelioms;InFo Hämatologie + Onkologie;2022-07-28

3. EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study;The Lancet Oncology;2022-06

4. Systemic treatment in patients with malignant pleural mesothelioma – real life experience;BMC Cancer;2022-04-20

5. Treatment Patterns and Outcomes of Patients With Advanced Pleural Mesothelioma at an Academic Referral Centre;Clinical Lung Cancer;2022-01